CTLA-4-话题@MedSci

#CTLA-4#

43篇内容 | 3040人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1461859, encodeId=90321461859a8, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=Arthritis Rheumatol：阿巴西普（CTLA-4Ig）治疗Takayasu动脉炎的随机双盲试验, objectType=article, longId=95068, objectId=8fa695068f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fa695068f2, replyNumber=0, likeNumber=80, createdTime=2017-04-09, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fa695068f2, moduleTitle=Arthritis Rheumatol：阿巴西普（CTLA-4Ig）治疗Takayasu动脉炎的随机双盲试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fa695068f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461858, encodeId=62741461858e5, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=NEJM：抗PD-1与抗CTLA-4一线治疗晚期黑色素瘤头对头比较，前者胜出（KEYNOTE-006研究）, objectType=article, longId=50142, objectId=85055014226, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85055014226, replyNumber=0, likeNumber=86, createdTime=2015-05-02, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85055014226, moduleTitle=NEJM：抗PD-1与抗CTLA-4一线治疗晚期黑色素瘤头对头比较，前者胜出（KEYNOTE-006研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85055014226)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461857, encodeId=1362146185ea5, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=Lancet Oncology：对抗CTLA-4药物治疗后进展的黑色素瘤疗效对比，Nivolumab V.S 化疗, objectType=article, longId=49613, objectId=47e349613d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47e349613d4, replyNumber=0, likeNumber=85, createdTime=2015-04-22, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47e349613d4, moduleTitle=Lancet Oncology：对抗CTLA-4药物治疗后进展的黑色素瘤疗效对比，Nivolumab V.S 化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47e349613d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461856, encodeId=42851461856cc, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=Trends Immunol：关于抗癌热门靶点CTLA-4的分子机制, objectType=article, longId=46625, objectId=9c334662574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c334662574, replyNumber=0, likeNumber=106, createdTime=2015-02-06, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c334662574, moduleTitle=Trends Immunol：关于抗癌热门靶点CTLA-4的分子机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c334662574)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CTLA-4

2020-05-29

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

Arthritis Rheumatol：阿巴西普（CTLA-4Ig）治疗Takayasu动脉炎的随机双盲试验

2017-04-09

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

NEJM：抗PD-1与抗CTLA-4一线治疗晚期黑色素瘤头对头比较，前者胜出（KEYNOTE-006研究）

2015-05-02

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

Lancet Oncology：对抗CTLA-4药物治疗后进展的黑色素瘤疗效对比，Nivolumab V.S 化疗

2015-04-22

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

Trends Immunol：关于抗癌热门靶点CTLA-4的分子机制

2015-02-06

科室
- - 订阅+
  - 更多科室
工具
服务